Does oral alpha lipoic acid prevent oxaliplatin-induced peripheral neuropathy? A randomized, double-blind, parallel-arm, placebo-controlled trial.
Maria Giuseppa Vitale(University of Modena and Reggio Emilia), Giacomo Cartenì(Ospedale Antonio Cardarelli), Felice Sirico(Ospedale Antonio Cardarelli), Giorgio Bedogni(Ospedale "Santa Maria delle Croci" di Ravenna), Carmela Barbato(Ospedale Antonio Cardarelli), Francesco Habetswallner(Ospedale Antonio Cardarelli), Bernardo Maria De Martino(Ospedale Antonio Cardarelli), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Maria Biglietto(Ospedale Antonio Cardarelli), Bruno Chiurazzi(Ospedale Antonio Cardarelli)
Cited by 0
Related Papers
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
|Annals of Oncology|2009|205
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180